Clinical trial
HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)
NCT04447352 · Krankenhaus Nordwest, Other · Recruiting
Key facts
| NCT number | NCT04447352 |
|---|---|
| Title | HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT) |
| Official title | Preventive HIPEC in Combination With Perioperative FLOT Versus FLOT Alone for Resectable Diffuse Type Gastric and Gastroesophageal Junction Type II/III Adenocarcinoma - The Phase III "PREVENT" Trial of the AIO /CAOGI /ACO |
| Acronym | PREVENT |
| Lead sponsor | Krankenhaus Nordwest, Other |
| Collaborators | Deutsche Krebshilfe e.V., Bonn (Germany) |
| Status | Recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma |
| Intervention type | Drug |
| Interventions | 5-Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel, Cisplatin |
| Enrollment | 200 |
| Start date | Dec 17, 2020 |
| Primary completion | Nov 1, 2026 |
| Completion | May 1, 2027 |
| First posted | Jun 25, 2020 |
| Last update posted | Nov 12, 2024 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: